Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
IPO Year: 2020
Exchange: NASDAQ
Website: zentalis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2024 | $4.00 | Underperform → Neutral | Wedbush |
| 6/20/2024 | $28.00 → $5.00 | Buy → Neutral | UBS |
| 6/18/2024 | $42.00 → $6.00 | Buy → Hold | Jefferies |
| 6/18/2024 | $38.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/18/2024 | $15.00 → $4.00 | Neutral → Underperform | Wedbush |
| 6/18/2024 | Overweight → Equal Weight | Wells Fargo | |
| 11/8/2023 | $38.00 → $12.00 | Outperform → Neutral | Wedbush |
| 11/7/2023 | $15.00 | Outperform → Market Perform | Leerink Partners |
| 7/12/2022 | Outperform | Cowen | |
| 4/6/2022 | $67.00 | Overweight | Wells Fargo |